Pharsight

Drugs that contain Apixaban

1. Eliquis patents expiration

ELIQUIS's oppositions filed in EPO
ELIQUIS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6413980 BRISTOL MYERS SQUIBB Nitrogen containing heterobicycles as factor Xa inhibitors
Dec, 2019

(4 years ago)

US6967208 BRISTOL MYERS SQUIBB Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945 BRISTOL MYERS SQUIBB Apixaban formulations
Feb, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-690) Aug 21, 2017
New Indication(I-661) Aug 21, 2017
New Indication(I-691) Aug 21, 2017
New Indication(I-681) Mar 03, 2017
New Chemical Entity Exclusivity(NCE) Dec 28, 2017

NCE-1 date: 28 December, 2016

Market Authorisation Date: 28 December, 2012

Treatment: Treatment of deep vein thrombosis (dvt); Prophylaxis of pulmonary embolism

Dosage: TABLET;ORAL

How can I launch a generic of ELIQUIS before it's drug patent expiration?
More Information on Dosage

ELIQUIS family patents

Family Patents